Group 1 - Chengdu Yiyuan Zhichuang Technology Co., Ltd. has completed a Pre-A round of financing, with the amount undisclosed, and the investment was participated by Ceyuan Capital [1] - The company specializes in digital medical services and the research and production of 3D personalized medical devices, positioning itself as a high-tech enterprise [2] - It possesses one of the few domestic teams capable of multi-modal digital reconstruction in the digital medical field, focusing on advanced technology research and application in medical 3D [2] Group 2 - The company has developed an open service system for medical 3D printing with independent intellectual property rights, providing leading personalized medical 3D solutions for clinical doctors and patients [2] - Chengdu Yiyuan Zhichuang has obtained over 30 patents and established one group standard [2]

Core Insights - Novo Nordisk announced a comprehensive upgrade of its "Health Ecosystem Alliance" at the 8th China International Import Expo, transitioning from a singular focus on digital healthcare to a collaborative cross-industry approach [1] Group 1: Digital Health Ecosystem - The "Health Ecosystem Alliance" aims to establish an "online + offline" intelligent chronic disease management network, integrating data from doctors, pharmaceutical companies, and medical devices to create a sustainable closed loop [2] - The alliance has partnered with major health platforms like Alibaba Health, JD Health, and Tencent Health to build a digital chronic disease management ecosystem, emphasizing early screening, diagnosis, and treatment [2] Group 2: Device Connectivity and Data Integration - Novo Nordisk will collaborate with Weitai Medical and Yuyue Medical to integrate insulin pen and dynamic blood glucose meter data, enabling visualized management of blood glucose and medication for patients [3] - The partnership with Huawei Health will incorporate exercise and heart rate data into the "Novo Care" platform, creating a comprehensive health profile for users [3] Group 3: Product Launches - The launch of the Harmony version of the "Novo Care" app, compatible with Huawei devices, and the weight management version focuses on providing customized health management solutions for diabetes, rare diseases, and obesity [4] - The new app versions aim to enhance user experience by offering features like disease education, smart medication guidance, and a "pharmacy map" [4] Group 4: Patient-Centric Approach - Novo Nordisk's senior vice president emphasized that digital innovation is reshaping chronic disease management, aiming to create a future-oriented health service model through collaboration with leading digital ecosystem partners in China [5] - The company's goal extends beyond drug innovation to enhancing public health literacy and supporting the "Healthy China" strategy through digital services [5]